A pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells, and its action on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs), has recently been described in breast cancer [129]. This evidence concerns the gene TLR4 and breast cancer.